Abstract
Gemcitabine is a widely used chemotherapy that interferes with tumor growth by targeting DNA replication. Understanding why many tumors are unresponsive to gemcitabine is a clinical challenge. A new study reports that upregulation of the cytidine deaminases APOBEC3C and APOBEC3D facilitates gemcitabine resistance by protecting against DNA replication stress.